The Safety of available immunotherapy for the treatment of glioblastoma

References

• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014 Oct;16(Suppl 4):iv1–63.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459–466.
   PubMed Web of Science ®Google Scholar
• Finlay JL, Boyett JM, Yates AJ, et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. childrens cancer group. J Clinl Oncol: off Jl Am Soc Clin Oncol. 1995 Jan;13(1):112–123.
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Piantadosi S, et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res: off J Am Assoc for Can Res. 2010 Apr 15;16(8):2443–2449.
   PubMed Web of Science ®Google Scholar
• Johnson DR, Ma DJ, Buckner JC, et al. Conditional probability of long-term survival in glioblastoma: a population-based analysis. Cancer. 2012 Nov 15;118(22):5608–5613.
   PubMed Web of Science ®Google Scholar
• Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol. 2003 Dec;30(6 Suppl 19):10–14.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007 Aug;114(2):97–109.
   PubMed Web of Science ®Google Scholar
• Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015 Jun 25;372(26):2499–2508.
   PubMed Web of Science ®Google Scholar
• Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res: off J Am Assoc for Can Res. 2014 Nov 15;20(22):5620–5629.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Freeman G, Wu C, et al. Immunotherapy advances for glioblastoma. Neuro Oncol. 2014 Nov;16(11):1441–1458.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Mitchell DA. Vaccination strategies for neuro-oncology. Neuro Oncol. 2015 Nov;17 Suppl 7:vii15–vii25.
   PubMed Web of Science ®Google Scholar
• Neagu MR, Reardon DA. An update on the role of immunotherapy and vaccine strategies for primary brain tumors. Curr Treat Options Oncol. 2015 Nov;16(11):54.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Wucherpfennig KW, Freeman G, et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013 Jun;12(6):597–615.
   PubMed Web of Science ®Google Scholar
• Liu G, Akasaki Y, Khong HT, et al. Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene. 2005 Aug 4;24(33):5226–5234.
   PubMed Web of Science ®Google Scholar
• Prins RM, Odesa SK, Liau LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 2003 Dec 1;63(23):8487–8491.
   PubMed Web of Science ®Google Scholar
• Xu LW, Chow KK, Lim M, et al. Current vaccine trials in glioblastoma: a review. J Immunol Res. 2014;2014:796856.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clinl Oncol: off Jl Am Soc Clin Oncol. 2010 Nov 1;28(31):4722–4729.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011 Mar;13(3):324–333.
   PubMed Web of Science ®Google Scholar
• Schuster J, Lai RK, Recht LD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun;17(6):854–861.
   PubMed Web of Science ®Google Scholar
• Liang F, Ploquin A, Hernandez JD, et al. Dissociation of skeletal muscle for flow cytometric characterization of immune cells in macaques. J Immunol Methods. 2015;425:69–78.
   PubMed Web of Science ®Google Scholar
• Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009 Aug;11(4):341–347.
   PubMed Web of Science ®Google Scholar
• Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature. 2014 Aug 21;512(7514):324–327.
   PubMed Web of Science ®Google Scholar
• Pollack IF, Jakacki RI, Butterfield LH, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clinl Oncol: off J Am Soc Clin Oncol. 2014 Jul 1;32(19):2050–2058.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. morphology, quantitation, tissue distribution. J Exp Med. 1973 May 1;137(5):1142–1162.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811.
   PubMed Web of Science ®Google Scholar
• Nair S, Archer GE, Tedder TF. Isolation and generation of human dendritic cells. Curr Protoc Immunol. Nov 2012;Chapter 7:Unit7 32
   PubMedGoogle Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012 Apr;12(4):265–277.
   PubMed Web of Science ®Google Scholar
• Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res: off J Am Assoc for Can Res. 2005 Aug 1;11(15):5515–5525.
   PubMed Web of Science ®Google Scholar
• Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clinl Oncol: off Jl Am Soc Clin Oncol. 2011 Jan 20;29(3):330–336.
   PubMed Web of Science ®Google Scholar
• Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother: CII. 2013 Jan;62(1):125–135.
   PubMed Web of Science ®Google Scholar
• Wen PY, Reardon DA, Phuphanich S, et al. A randomized, double-blind, placebo-controlled phase 2 trial of dendritic cell (DC) vaccination with ICT-107 in newly diagnosed glioblastoma (GBM) patients. J Clin Oncol. 2014 May 20;32(15):5s.
   PubMed Web of Science ®Google Scholar
• Lucas KG, Bao L, Bruggeman R, et al. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol. 2011 Jun;103(2):231–238.
   PubMed Web of Science ®Google Scholar
• Soderberg-Naucler C, Johnsen JI. Cytomegalovirus in human brain tumors: role in pathogenesis and potential treatment options. World J Exp Med. 2015 Feb 20;5(1):1–10.
   PubMedGoogle Scholar
• Fuji S, Kapp M, Grigoleit GU, et al. Adoptive immunotherapy with virus-specific T cells. Best Pract Res Clinl Haematol. 2011 Sep;24(3):413–419.
   PubMed Web of Science ®Google Scholar
• Mitchell DA, Batich KA, Gunn MD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015 Mar 19;519(7543):366–369.
   PubMed Web of Science ®Google Scholar
• Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg. 1999 Jun;90(6):1115–1124.
   PubMed Web of Science ®Google Scholar
• Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004 Jul 15;64(14):4973–4979.
   PubMed Web of Science ®Google Scholar
• De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res: off J Am Assoc for Can Res. 2008 May 15;14(10):3098–3104.
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res: off J Am Assoc for Can Res. 2005 Jun 1;11(11):4160–4167.
   PubMed Web of Science ®Google Scholar
• Fadul CE, Fisher JL, Hampton TH, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunotherapy. 2011 May;34(4):382–389.
   PubMed Web of Science ®Google Scholar
• Ardon H, Van Gool SW, Verschuere T, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother: CII. 2012 Nov;61(11):2033–2044.
   PubMed Web of Science ®Google Scholar
• Polyzoidis S, Ashkan K. DCVax(R)-L–developed by Northwest biotherapeutics. Hum Vaccin Immunother. 2014;10(11):3139–3145.
   PubMed Web of Science ®Google Scholar
• Ampie L, Choy W, Lamano JB, et al. Heat shock protein vaccines against glioblastoma: from bench to bedside. J Neurooncol. 2015 Jul;123(3):441–448.
   PubMed Web of Science ®Google Scholar
• Christians ES, Zhou Q, Renard J, et al. Heat shock proteins in mammalian development. Semin Cell Dev Biol. 2003 Oct;14(5):283–290.
   PubMed Web of Science ®Google Scholar
• Crane CA, Han SJ, Ahn B, et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res: off J Am Assoc for Can Res. 2013 Jan 1;19(1):205–214.
   PubMed Web of Science ®Google Scholar
• Bloch O, Crane CA, Fuks Y, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014 Jan;16(2):274–279.
   PubMed Web of Science ®Google Scholar
• Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168–16173.
   PubMed Web of Science ®Google Scholar
• Suryadevara CM, Verla T, Sanchez-Perez L, et al. Immunotherapy for malignant glioma. Surg Neurol Int. 2015;6(Suppl 1):S68–77.
   PubMedGoogle Scholar
• Schuessler A, Smith C, Beagley L, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014 Jul 1;74(13):3466–3476. .
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Therapy:J Am Soc Gene Ther. 2010 Apr;18(4):843–851.
   PubMed Web of Science ®Google Scholar
• Bonini C, Mondino A. Adoptive T-cell therapy for cancer: the era of engineered T cells. Eur J Immunol. 2015 Sep;45(9):2457–2469.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011 Aug 25;365(8):725–733.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507–1517.
   PubMed Web of Science ®Google Scholar
• Brown CE, Badie B, Barish ME, et al. Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res: off J Am Assoc for Can Res. 2015 Sep 15;21(18):4062–4072.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188–195.
   PubMed Web of Science ®Google Scholar
• Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. New Engl J Med. 2011 May 12;364(19):1844–1854.
   PubMed Web of Science ®Google Scholar
• Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv Immunol. 2006;90:297–339.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015 Jan 22;372(4):320–330.
   PubMed Web of Science ®Google Scholar
• McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol. 1999 Feb;77(1):1–10.
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009 Aug 3;206(8):1717–1725.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Apr;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012 May;13(5):459–465.
   PubMed Web of Science ®Google Scholar
• Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007 Jan;13(1):84–88.
   PubMed Web of Science ®Google Scholar
• Han SJ, Ahn BJ, Waldron JS, et al. Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. Neuroreport. 2009 Dec 9;20(18):1597–1602.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Kiesel B, Widhalm G, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015 Aug;17(8):1064–1075.
   PubMed Web of Science ®Google Scholar
• Hernandez-Pedro NY, Rangel-Lopez E, Vargas Felix G, et al. An update in the use of antibodies to treat glioblastoma multiforme. Autoimmune Dis. 2013;2013:1–14.
   Google Scholar
• Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell. 2002 Apr;1(3):219–227.
   PubMed Web of Science ®Google Scholar
• Johnson DR, Leeper HE, Uhm JH. Glioblastoma survival in the United States improved after food and drug administration approval of bevacizumab: a population-based analysis. Cancer. 2013 Oct 1;119(19):3489–3495.
   PubMed Web of Science ®Google Scholar
• Fu P, He YS, Huang Q, et al. Bevacizumab treatment for newly diagnosed glioblastoma: systematic review and meta-analysis of clinical trials. Mol Clin Oncol. 2016 May;4(5):833–838.
   PubMedGoogle Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):699–708.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):709–722.
   PubMed Web of Science ®Google Scholar
• Mishima K, Johns TG, Luwor RB, et al. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 2001 Jul 15;61(14):5349–5354.
   PubMed Web of Science ®Google Scholar
• Patel D, Lahiji A, Patel S, et al. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res. 2007 Sep-Oct;27(5A):3355–3366.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Crotty LE, Lee S, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. P Natl Acad Sci USA. 2000 Jun 20;97(13):7503–7508.
   PubMed Web of Science ®Google Scholar
• Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncology: off J Eur Soc Med Oncol /ESMO. 2009 Sep;20(9):1596–1603.
   PubMed Web of Science ®Google Scholar
• Liu S, Kurzrock R. Understanding toxicities of targeted agents: implications for anti-tumor activity and management. Semin Oncol. 2015 Dec;42(6):863–875.
   PubMed Web of Science ®Google Scholar
• Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers. 2011;3(4):3856–3893.
   PubMedGoogle Scholar
• Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS: Acta Pathologica, Microbiologica, Et Immunologica Scandinavica. 1995 Mar;103(3):161–179.
   PubMed Web of Science ®Google Scholar
• Ridolfi L, de Rosa F, Ridolfi R, et al. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response. J Transl Med. 2014;12:262.
   PubMed Web of Science ®Google Scholar
• Di Trolio R, Simeone E, Di Lorenzo G, et al. The use of interferon in melanoma patients: a systematic review. Cytokine Growth Factor Rev. 2015 Apr;26(2):203–212.
   PubMed Web of Science ®Google Scholar
• Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer. 2009 Aug 18;101(4):615–620.
   PubMed Web of Science ®Google Scholar
• Ray S, Bonafede MM, Mohile NA. Treatment patterns, survival, and healthcare costs of patients with malignant gliomas in a large US commercially insured population. Am Health Drug Benefits. 2014 May;7(3):140–149.
   PubMedGoogle Scholar
• Kutikova L, Bowman L, Chang S, et al. Utilization and cost of health care services associated with primary malignant brain tumors in the United States. J Neurooncol. 2007 Jan;81(1):61–65.
   PubMed Web of Science ®Google Scholar
• Killela PJ, Reitman ZJ, Jiao Y, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021–6026.
   PubMed Web of Science ®Google Scholar
• Hoos A, Britten C. The immuno-oncology framework: enabling a new era of cancer therapy. Oncoimmunology. 2012 May 1;1(3):334–339.
   PubMed Web of Science ®Google Scholar
• Sampson JH. Alternating electric fields for the treatment of glioblastoma. JAMA. 2015 Dec 15; 314(23):2511–2513.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015 Dec 15;314(23):2535–2543.
   PubMed Web of Science ®Google Scholar